Kornimate/medical-research-clean huggingface dataset:
comparative study of clinical outcomes and safety between colistin and tigecycline

Conditions: Infection in ICU

Summary: objective from this study to compare the clinical outcomes and safety between colistin and tigecycline for multi-drug resistant gram negative bacteria.

study will be in beni-suef university hospital. group i: 66 patients received intravenous colistin 300 mg colistin base activity (cba) as loading dose, followed by 2.5-5mg/kg/day of cba in 2 divided doses as a maintenance dose in intensive care unit to treat their mdr infection and group 2 contains 66 patients received intravenous tigecycline100 mg single dose as loading dose, followed by 25-50 mg every 12 hours maintenance dose in intensive care unit to treat their mdr infection

Eligibility criteria:
inclusion criteria: study will include * adult patient (male, female) * age from 18 to 70 years * patients admitted to intensive care unit in study period (six months) who received intravenous colistin or tigecycline as antimicrobial drug for treatment their mdr gram negative infection. exclusion criteria: * patient admitted to intensive care unit younger than 18 years or older than 70 years. * liver transplantation patients. * patients are chronic kidney disease (ckd on hemodialysis or baseline creatinine clearance (crcl) \< 10 ml/min (estimated by cockcroft gault equation). * patients received renal replacement therapy before or during admission. * patient is on any other nephrotoxic drug (vancomycin, aminoglycosides, nsaids, cyclosporine, amphotericin b, etc.). * pregnant and lactating women. * patients refused the consent of the study.

Keywords: colistin tigecycline renal impairment
calcium for out-of-hospital cardiac arrest

Conditions: Heart Arrest, Out-Of-Hospital

Summary: this is an investigator-initiated, multicenter, randomized, placebo-controlled, parallel group, double-blind, superiority trial of calcium during adult out-of-hospital cardiac arrest. 430 adult patients with out-of-hospital cardiac arrest receiving at least one dose of adrenaline will be enrolled. the primary outcome is sustained return of spontaneous circulation and key secondary outcomes include survival at 30 days and survival at 30 days with a favorable neurological outcome.


Eligibility criteria:
inclusion criteria: * out-of-hospital cardiac arrest * age ≥ 18 years * received at least one dose of adrenaline exclusion criteria: * traumatic cardiac arrest - including drowning and external asphyxia (e.g., hanging, strangulation, or foreign object airway obstruction) * known or strongly suspected pregnancy * prior enrollment in the trial * received adrenaline during cardiac arrest before arrival of prehospital personnel with the study drug * clinical indication for calcium administration during the cardiac arrest
a study to learn about somatrogon in patients with pediatric growth hormone deficiency (p ghd) in india.

Conditions: Dwarfism, Pituitary

Summary: the purpose of this study is to learn about the safety of somatrogon for the treatment of pediatric growth hormone deficiency (p ghd) in india. pediatric ghd is a condition caused by too less amounts of growth hormone in the body. children with ghd have a short height. ghd can be present at birth or develop later. the condition occurs if the pituitary gland makes too little growth hormone. this is a small gland at the bottom of the brain that releases hormones that affect growth and other body functions. this study is seeking for participants who are: * confirmed with p ghd. * given somatrogon to be taken as an injection. the safety of somatrogon injection will be checked based on side effects. these side effects can happen within 3 years after taking somatrogon. a side effect is something (expected or unexpected) that you feel was caused by a medicine or treatment you take. the study doctor will collect side effect information and put the information on patient's case form. follow-up of the patient's will be performed via clinic re-visit or over a call. it is not a rule for the participants to visit the clinic in this study. this study will help to see if somatrogon is safe.


Eligibility criteria:
inclusion criteria: * prescription of somatrogon for p ghd in participants aged 3 years or more. * evidence of a personally signed and dated informed consent document indicating that the participant (or a legally acceptable representative) has been informed and agree to all pertinent aspects of the study. assent will also be sought from children of applicable age in line with national guidance. in all cases, the treating physician responsible for enrolling the participant into the study will assess the appropriateness of gaining assent from a participant (or a legally acceptable representative) at their discretion during routine clinical care. exclusion criteria: * participation in any interventional clinical trials at the time of enrollment.

Keywords: somatrogon, safety
prevalence and risk factors for common diseases

Conditions: Cardiovascular Diseases; Fracture; Cancer

Summary: by using national databases in sweden the aim of the present project is to: 1. investigate if the incidence of our most common diseases, such as fracture and cardiovascular disease, has changed from 1970-2017 2. to investigate whether the risk of death for our most common diseases have changed from 1970-2017. 3. to investigate the risk of a new episode after suffering from our most common diseases from 1970-2017 4. to investigate the risk factors for our most common diseases, and whether these have changed from 1970. 5. to investigate how severe disease or death affects the health of a close relative.

please see above on the summary.

Eligibility criteria:
inclusion criteria: * all people living in sweden that is diagnosed with our most common diseases between 1970-2017. exclusion criteria: * none
a pragmatic trial of the consult for addiction treatment and care in hospitals (catch) model for engaging patients in opioid use disorder treatment

Conditions: Opioid Dependence; Opioid Abuse

Summary: this pragmatic clinical trial seeks to evaluate the effectiveness of the consult for addiction treatment and care in hospitals (catch) intervention as a strategy for engaging patients with opiod use disorder (oud) in addiction treatment.

the overarching objective of our study is to evaluate the effectiveness of catch as a strategy for engaging patients with oud in mat. a pragmatic trial at 6 hospitals, conducted in collaboration with the new york city health and hospitals system (h+h) and the new york city department of health and mental hygiene (dohmh), will study the catch intervention in real-world settings and at scale. guided by the re-aim evaluation framework, this hybrid effectiveness-implementation study (type 1) focuses primarily on effectiveness, but also measures implementation outcomes to inform the intervention's adoption and sustainability. a rigorous stepped-wedge cluster randomized trial design determines the impact of catch on opioid treatment outcomes in comparison to usual care for a control period, followed by a 12-month intervention period and a maintenance period, and utilizes existing administrative data to evaluate outcomes. aim 1 (primary aim) is to evaluate the effectiveness of catch in increasing post-discharge initiation and engagement in mat, defined respectively as receiving outpatient mat within 14 days of discharge, and having at least 2 additional mat visits in the first month. aim 2 is to assess the effectiveness of catch for increasing treatment retention, defined as continuous receipt of mat for 6 months. aim 3 is to compare the frequency of acute care utilization and overdose deaths, and their associated costs, among patients with oud who are hospitalized during the catch period versus usual care. aim 4 is to evaluate implementation outcomes at catch sites using a mixed methods approach to assess the intervention's reach (proportion of eligible patients reached); adoption (utilization by medical staff); and implementation fidelity (barriers to delivering high-quality mat).

Eligibility criteria:
inclusion criteria: * adult patients (≥18 years); * hospitalized for at least 1 night on an inpatient service (not including intensive care); * admission or discharge diagnosis (based on icd-10 codes) of opioid use disorder or opioid poisoning. cases are excluded if they received mat (buprenorphine, methadone maintenance treatment, or naltrexone) in the 30 days prior to admission. cases included in the intervention condition must have been admitted on a date following implementation of catch. exclusion criteria: * lack of fluency in english, unable to provide informed consent.
pf and feno and clinical characteristics in children being diagnosed due to suspicion of allergic diseases

Conditions: Asthma; Allergic Rhinitis; Atopic Dermatitis; Urticaria; Healthy

Summary: the aim of this study is to assess the influence of kind of allergic disease, allergic profile, allergen exposure, treatment method on lung function parameters, fractional exhaled nitric oxide level in children suspected and being diagnosed due to allergic diseases.

the aim of this study is to assess the influence of kind of allergic disease, allergic profile, allergen exposure, treatment method on lung function parameters, fractional exhaled nitric oxide (feno) level in children suspected and being diagnosed due to allergic diseases. study will be retrospective, conducted in all children diagnosed in the years of 2005-20012 in laboratory of lung function tests of department of pediatrics and allergy, medical university of lodz, n. copernicus hospital, lodz, poland. the investigators will analyse 5500 male an female children 5-18 year old suspected and being diagnosed due to allergic diseases. in these children nearly 3000 feno measurements, 65000 spirometry measurements, 22000 whole-body plethysmography measurements and 48000 occlusion resistance measurements were performed between the years of 2005-2012. the investigators will retrospectively evaluate following data from medical documentation of patients: 1. feno levels. 2. allergic disease diagnosis. 3. immunoglobulin e (ige) specific levels. 4. treatment (drugs and dosages). 5. lung function parameters (spirometry, whole-body plethysmography, occlusion resistance, bronchial reversibility test).

Eligibility criteria:
inclusion criteria: * children with allergic diseases, healthy children. exclusion criteria: * other serious diseases.

Keywords: children asthma allergic rhinitis atopic dermatitis urticaria healthy
influence of original native aortic valve lesion (stenosis or steno-insufficiency vs. insufficiency) on post-implant structural bioprosthetic degeneration after aortic valve replacement

Conditions: Aortic Bioprosthesis Degeneration

Summary: all patients undergoing elective aortic valve replacement for stenotic aortic valve replacement or aortic valve regurgitation at our institution from 2012 to 2021 who met the inclusion criteria for the study (described in the dedicated session) will be enrolled in the study. these patients will be contacted to provide information about the clinical status, nyha functional class, possible rehospitalization, possible cardiovascular events and to perform a postoperative echocardiography if not performed in the previous year. once consent is given, pre-, intra- and post-operative data will be collected in a dedicated, structured, database.

all patients undergoing elective aortic valve replacement for stenotic aortic valve replacement or aortic valve regurgitation at our institution from 2012 to 2021 who met the inclusion criteria for the study (described in the dedicated session) will be enrolled in the study. these patients will be contacted to provide information about the clinical status, nyha functional class, possible rehospitalization, possible cardiovascular events and to perform a postoperative echocardiography if not performed in the previous year. once consent is given, pre-, intra- and post-operative data will be collected in a dedicated, structured, database.

Eligibility criteria:
inclusion criteria: * - age ≥ 18 years; 9 * patients who underwent isolated aortic and mitral valve replacement for stenosis or regurgitation * signed informed consent, inclusive of release of medical information. exclusion criteria: * - aortic and mitral valve replacement associated with surgery of ascending aorta/aortic root; * aortic and mitral valve replacement associated with other cardiac valve surgery (apart from arrythmia-related ablation or procedures); * previous cardiac surgery of any kind; * surgery for acute endocarditis * surgery for type a aortic dissection * participation in another clinical trial that could interfere with the endpoints of this study. * pregnant or breastfeeding at time of screening.

Keywords: aortic bioprosthesis bioprosthesis degeneration
tri-v heart failure (hf) implanted cardioverter defibrillator (icd) study

Conditions: Heart Failure

Summary: it's the aim of this study to investigate the impact of right ventricular (rv) lead position (rv-apex, his bundle area, rv-apex+his bundle area) in combination with individually optimized left ventricular (lv) lead placement and crt timing on the outcome of cardiac resynchronization therapy (crt).


Eligibility criteria:
inclusion criteria: * patient with indication for crt-d: nyha iii-iv congestive heart failure, in spite of optimal medical treatment for their congestive heart failure * lvedd \> 55 mm or \> 30 mm/m² bsa * ef \< 35% * sinus rhythm and one of the following criteria: * qrs \>= 120 ms and pq \>= 200ms * or * 2nd / 3rd degree av block * written informed consent exclusion criteria: * pacemaker indication (without icd indication) * tricuspidal valve and/or aortic valve replacement * indication for revascularization. * less than 3 month after heart surgery or myocardial infarction * hypertrophic obstructive cardiomyopathy * intravenous catecholamine treatment * uncorrected thyroid function * severe kidney disorder (creatinin \>2,5mg%) * no written patient consent * insufficient patient compliance * participating in another study * life expectancy \< 1 year due to other severe disease * age \< 18 years * no contraception (young women) or pregnancy

Keywords: heart failure (nyha class iii and iv) ventricular dyssynchrony
acute pharmacokinetic-pharmacodynamic change of rocuronium after reperfusion of renal graft

Conditions: End Stage Renal Disease; Transplantation

Summary: reperfusion of renal graft in kidney transplantation can change the pharmacokinetic-pharmacodynamic (pkpd) parameters of rocuronium. the immediate increase of urine output during surgery may change the pkpd parameters of the drugs, including elimination rate. the goal of this study is to characterize the pkpd model of rocuronium during kidney transplantation and establish a basis for adequate dosage of rocuronium in kidney transplantation. through pkpd modeling, the changes during reperfusion of the renal graft will be evaluated. furthermore, the factors related to the changes will be assessed. adjusting the infusion rate according to the step of kidney transplantation will lead to stable muscle relaxation and fast recovery.


Eligibility criteria:
inclusion criteria: * patients scheduled for elective living donor kidney transplantation * end stage renal disease with oliguria or anuria * normal bmi (bmi 18.5 \~ 25) * obtained informed consent exclusion criteria: * patient with underlying neuromuscular disease
retrospective case series of trans-scleral cryotherapy for retinal hemangioblastoma

Conditions: Retinal Hemangioblastoma; Von Hippel-Lindau Disease

Summary: background: retinal hemangioblastoma (rh) is a tumor. it grows from the retina in the eye. it can threaten a person s vision. trans-scleral cryotherapy is used to destroy the tumors and minimize the long-term risks of vision loss. rh is a rare condition, often occurring in people with von hippel-lindau disease. there are no clinical trials to study how well the treatment works. researchers want to study the medical records of people with rh who were treated at the nih eye clinic to learn more. objective: to analyze clinical data collected over a 20-year span to study consecutive cases of rh managed with trans-scleral cryotherapy at the nih. eligibility: people who took part in nih natural history protocols for which cryotherapy of rh was performed as a standard care measure. design: researchers will collect and study data from participants medical charts. participants will not be contacted because no new data is needed. researchers were granted a waiver of informed consent for use of these medical records. to protect patient privacy, participants will be assigned an id number. their data will be entered into a spreadsheet in a coded fashion. the key to this code will be kept in a secure file. no patient identifying information will be used in the analysis or the publication....

study description: this study is a retrospective review of medical records in the nih eye clinic. to our knowledge, there has been no report in the current era dedicated to a description of trans-scleral cryotherapy for retinal hemangioblastomas despite its routine use in this setting. this study aims to explore features and outcomes of these cases to better inform best practices. objectives: the objective of this study is to perform a retrospective analysis of consecutive cases of retinal hemangioblastoma managed with trans-scleral cryotherapy at the nih (single center retrospective case series).

Eligibility criteria:
* inclusion criteria: 1. participants were enrolled in nei and non-nei natural history protocols, but in all cases, cryotherapy was administered as a standard care measure (not as an investigative treatment). 2. patients were identified by searching the nih eye clinic emr for all of those manifesting one or more retinal hemangioblastomas (with or without associated von hippel-lindau disease) treated with cryotherapy. exclusion criteria: none

Keywords: vascular tumor vision loss natural history
a study of the safety and efficacy of a-60444 in adults with respiratory syncytial virus (rsv) infection following hsct

Conditions: Respiratory Syncytial Virus Infections

Summary: objectives primary objectives: * pilot study: a preliminary assessment of the exposure and safety of oral a-60444 in post-stem cell transplant patients with rsv infection. * main study: to determine the antiviral effect of oral a-60444 versus placebo in post-stem cell transplant patients with rsv infection and to assess the safety of oral a-60444 in post-stem cell transplant patients with rsv infection. secondary objectives: * to study the pharmacokinetics of a-60444 in the presence of concomitant medications such as immunosuppressants and antifungals, in post-stem cell transplant patients with rsv infection. sample size: six patients will be included in the open, pilot phase of the study and there is an option to include a further 22 patients into the main, placebo-controlled study, depending on the pilot study findings. an independent data safety monitoring board will assess the findings of the pilot study.

clinical will be recorded daily. a-60444 pk will be studied pre-dose and at peak dose on the last day (day 5) of dosing.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with rsv infection who have had a stem cell transplant. 2. female patients must be of non-childbearing potential or have a negative pregnancy test prior to study start and be deemed not at risk of becoming pregnant. females of non-childbearing potential are defined as women who have had a hysterectomy, bilateral oophorectomy, tubal ligation, or who have been post-menopausal for at least two years; or are considered to be sterile due to recent chemotherapy. 3. aged between 18 and 65 years. 4. patients who have given their written informed consent to participate in the study. 5. patients who are willing and able to comply with the protocol and study procedures. exclusion criteria: 1. patients who have received an investigational drug within one month preceding the start of dosing. 2. patients who have a documented history of allergy to benzodiazepines. 3. patients with significant hepatic impairment (alanine transaminase \[alt\] more than 5 x upper level of normal \[uln\], total bilirubin more than 3 x uln). biochemistry data collected four weeks prior to screening is acceptable. 4. patients, who in the opinion of their general practitioner or the investigator, should not participate in the study.

Keywords: rsv hsct hematopoietic stem cell transpl
hybrid score to predict otva-soo in patients with wide basal qrs

Conditions: ECG; Ventricular Arrhythmias; Catheter Ablation

Summary: outflow tract ventricular arrhythmia (otva) is the most common type of ventricular arrhythmia, and catheter ablation (ca) is the primary treatment option for patients experiencing symptoms. accurately identifying the origin site of otva is essential for effective catheter ablation, minimizing procedural risks, and enhancing treatment success. however, most studies that developed algorithms or scoring systems for distinguishing otva origins excluded participants with structural heart disease and those with paced rhythms from their study groups. a recent prospective evaluation of a hybrid score (hs) that integrates both clinical and ecg data to predict otva-soo, including patients with cardiac implantable electronic devices and those with structural heart disease in our study. the presented study aimed to assess the effectiveness of the previously described hybrid algorithm in predicting otva-soo in a patient population characterized by a wide basal qrs due to intraventricular conduction defects or paced rhythms. the hybrid score the hybrid score (hs), involves a sum of points based on clinical and ecg characteristics. points are assigned as follows: one point each for being over 50 years old, male, and having arterial hypertension. ecg-based points are allocated according to qrs transition: 3 points for a transition in v1, 2 points for v2, 1 point for v3 if the r-wave in v3 is greater than 1 mv; 1 point is subtracted if v3 has an r-wave less than 1 mv, and further deductions or additions apply for transitions up to v6. a score ≤ 1 suggests an rvot origin, whereas ≥ 2 suggests an lvot origin. ecgs were recorded with a standard configuration at a 25 mm/s sweep speed. premature ventricular contraction (pvc) ablation activation mapping of spontaneous otvas was conducted. the procedure aimed to abolish spontaneous otvas, with the site of ablation marking the site of origin (soo). collected data * patient information and consent (procedure must be done within 60 days of consent) * demographics (age, gender, etc.) * vital signs (length, weight, etc.) * medical history, including cardiovascular risk factors, cardiomyopathy and drugs * ecg data * echocardiographic data (left ventricular ejection fraction and left ventricular end-diastolic diameter) * procedure data (number of radiofrequency applications, site of effective ablation, total radiofrequency time, total fluoro time, points mapping, procedure time) * adverse events


Eligibility criteria:
inclusion criteria: * ventricular arrhythmia with a morphology indicating an outflow tract origin and a wide basal qrs complex * a qrs width greater than 110 ms was considered wide * willing and capable of providing written informed consent to the study exclusion criteria: * catether ablation procedure was unsuccessful * infrequent arrhythmia requiring ablation guided by pacemapping.

Keywords: ventricular extrasystole premature ventricular complex ecg outflow tract ventricular arrhythmias